Effects of Cerebrolysin®, donepezil, and the combination therapy on plasma neuronal-derived extracellular vesicles (NDEV) levels of: (a) Aβ1–42, (b) total-tau, (c) P-T181-tau, and (d) P-S396-tau at week 28 (end of the study) in patients with mild-to-moderate AD. (a) *p < 0.05 versus donepezil and Cerebrolysin® groups; (b, c, d) *p < 0.05 versus donepezil group. Data are presented as LS mean (±SE) change from baseline of natural log (nL) values and were analyzed by ANCOVA.